N-Thiolated B-lactams represent a novel family of antibacterial agents, whose in vitro activity is confined largely to Staphylococcus species, including multidrug-resistant forms of S. aureus. N-Thiolated B-lactams have recently been shown to possess intriguing biological activities which are addressed in Chapter II. Current development of nanoparticles as a new drug delivery vehicle is described in Chapter III. Chapter IV and V described the current research in our laboratories focusing on the synthesis and characterization of emulsified polyacrylate/polyacrylamide nanoparticle antibacterials for drug delivery of water-insoluble antibiotics. These nanoparticles can be prepared in aqueous media directly from acrylate/acrylamide monomers through free radical microemulsion polymerization. These emulsions contain antibiotic-conjugated polyacrylate nanospheres measuring 30-60 nm in diameter and have enhanced antibacterial activity against drug resistant S. aureus (MRSA) through what we believe is a novel mechanism.

Thesis (Ph.D.)--McMaster University (Canada), 1991. / Source: Dissertation Abstracts International, Volume: 54-02, Section: B, page: 0835.

Thesis (Ph. D.)--University of Washington, 2007. / Vita. Includes bibliographical references (leaves 186-197).

Thesis (doctoral)--Lund University, 1998. / Thesis statement on t.p. verso. Includes bibliographical references.

Stuttgart, Univ., Diss., 2002.

Stuttgart, Univ., Diss., 2005.

Thesis (doctoral)--Lund University, 1998. / Thesis statement on t.p. verso. Includes bibliographical references.

Thesis (Ph. D.)--Miami University, Dept. of Chemistry and Biochemistry, 2004. / Title from second page of PDF document. Includes bibliographical references.

Class of 2017 Abstract / Objectives: The objective of this retrospective cohort chart review was to evaluate the safety and efficacy of extended infusion beta-lactam regimens as part of treatment of acute CF pulmonary exacerbations in adults and pediatric patients. Methods: Inclusion criteria: adult and pediatric patients (age 1 month or older) with CF diagnosis who were admitted to BUMC-T for acute pulmonary CF exacerbation, and who received meropenem, imipenem, aztreonam, piperacillin-tazobactam, and or cefepime during their hospitalization (between 1/1/2011 and 10/30/2015). Exclusion criteria: pregnant women and admissions less than 24 hours. The two groups evaluated were patients receiving treatment (group 1) prior to extend infusion practices (Jan 2011 – Dec 2012) and (group 2) after implementation of extend infusion practices (Jan 2013 – Oct 2015). Data was collected from medical records using both the Sunrise Clinical Manager and EPIC electronic medical record systems. The data was then analyzed for differences in efficacy outcomes (e.g., length of hospitalization, lung function, return to baseline lung function), changes in renal and hepatic function, incidence of documented adverse drug effects, and potential factors associated with increased risk for changes in renal or hepatic function with use of extended infusion beta‐lactam regimens. Results: Pending. Efficacy outcomes: - length of hospitalization - improvement in lung function - return to baseline lung function Safety outcomes: - changes in renal and hepatic function - incidence of documented adverse drug effects - potential factors associated with increased risk for changes in renal or hepatic function Conclusions: Pending. As this study is being conducted at one academic medical center, conclusions may not be generalizable to other institutions.

No description available.